# OPDUALAG

NDC: 0003-7125
Generic name: nivolumab and relatlimab-rmbw
Labeler / Manufacturer: E.R. Squibb & Sons, L.L.C.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAVENOUS
Marketing started: 20220318

FDA application: BLA761234

## Active ingredients

- NIVOLUMAB: 12 mg/mL
- RELATLIMAB: 4 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0003-7125"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0003-7125
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b22c9d83-3256-4e17-85f7-f331a504adc6